Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brigit Biofarmaka Teknologi Tbk. (OBAT) vs Reksa Dana Indeks Premier ETF MSCI Indonesia Large Cap (XIML) Price & Performance

Brigit Biofarmaka Teknologi Tbk.Trade
Reksa Dana Indeks Premier ETF MSCI Indonesia Large CapTrade

Price performance (Past 24H)

Key statistics

Brigit Biofarmaka Teknologi Tbk. vs Reksa Dana Indeks Premier ETF MSCI Indonesia Large Cap — how do they compare? Brigit Biofarmaka Teknologi Tbk. trades at Rp240 (market cap 166.01B, 324K 24h volume), while Reksa Dana Indeks Premier ETF MSCI Indonesia Large Cap trades at Rp195 (market cap 34.24B, 20.1K 24h volume). The key difference: Brigit Biofarmaka Teknologi Tbk. is far larger — about 4.8× Reksa Dana Indeks Premier ETF MSCI Indonesia Large Cap's market cap, and Brigit Biofarmaka Teknologi Tbk. is more actively traded (324K versus 20.1K). Which is the better fit depends on your goals.

OBATXIML
Market Cap
166.01B34.24B
Volume
324K20.1K
Lot
3.24K201
Turnover
77.68M3.88M
Average Price
239.75193.01
Value
77.68M3.88M
Indicative Equilibrium Price
240
Indicative Equilibrium Volume
1

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

OBAT
View details

About Brigit Biofarmaka Teknologi Tbk.

PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.

Read more on OBAT

About Reksa Dana Indeks Premier ETF MSCI Indonesia Large Cap

Read more on XIML